Altimmune company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Loan | IPO

Total Raised


About Altimmune

Altimmune is an immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases.

Altimmune Headquarter Location

910 Clopper Road Suite 201S

Gaithersburg, Maryland, 20878,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Altimmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Altimmune is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Altimmune Patents

Altimmune has filed 33 patents.

The 3 most popular patent topics include:

  • Vaccines
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Vaccines, Clusters of differentiation, Transcription factors, Immunology, Immune system


Application Date


Grant Date



Related Topics

Vaccines, Clusters of differentiation, Transcription factors, Immunology, Immune system



Latest Altimmune News

Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

May 20, 2022

Gaithersburg, Maryland, UNITED STATES GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials. Details for the oral presentation are as follows: Title:

Altimmune Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Altimmune Rank

  • When was Altimmune founded?

    Altimmune was founded in 1997.

  • Where is Altimmune's headquarters?

    Altimmune's headquarters is located at 910 Clopper Road, Gaithersburg.

  • What is Altimmune's latest funding round?

    Altimmune's latest funding round is Loan.

  • How much did Altimmune raise?

    Altimmune raised a total of $64.03M.

  • Who are the investors of Altimmune?

    Investors of Altimmune include Cue Ball Capital.

  • Who are Altimmune's competitors?

    Competitors of Altimmune include Fujirebio, Molmed, Hawaii Biotech, DermTech International, Vaccinogen and 11 more.

You May Also Like

Efficas Logo

Efficas is a biotechnology company focused on the discovery and rapid development of nutritional bioactives with clinically-proven efficacy for the management of human and animal health. Efficas' lead product will be a product derived from an edible fruit to assist in the control of atopic dermatitis.

Origin BioMed

Origin BioMed Inc., is an innovative biotechnology company currently expanding the markets for its exclusive pain relief,diabetic, skin and lip care products.


BioJENC is a biotech company developing peptide vacines against human immunodeficiency virus (HIV) and other challenging infectious agents.

Zetra Biologicals

Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.


TechnoVax is a privately held biotechnology company and specializes in vaccine development. The company aims to begin clinical trials within the next 18 months.

Nabi Biopharmaceuticals

has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.